Home
Resources
Publications
[ 170 Tm]-Labeled ethylenediamine tetramethylene phosphonic acid

[ 170 Tm]-Labeled ethylenediamine tetramethylene phosphonic acid

Arvind Chopra

PMID: 21656985

Abstract:

Due to the metastases of cancer in the skeletal tissue, severe bone pain affects the quality of life of most patients suffering from malignancies of the breast, prostate, lungs, thyroid, or kidneys (2, 3). Although several interventions such as analgesics, bisphosphonates, hormone therapy, and systemic radionuclide therapy are available to manage the pain, these treatments are known to have many undesirable secondary effects (3). Radiopharmaceuticals that contain nuclides, such as strontium-89 (as 89SrCl2) and samarium-153 (administered as 153Sm-ethylenediamine tetramethylene phosphonic acid (EDTMP)), which are commonly used for palliative care of pain in the bones of these cancer patients, have been approved by the United States Food and Drug Administration (FDA) for the treatment of this condition (3). However, these are not the most ideal agents to treat pain due to bone metastases because the radionuclide either has a long half-life and generates high-energy β- particles (89Sr has a half-life of ~50 days and Eβ(max) = 1.49 MeV) or is short-lived and has to be produced in close vicinity to the treatment center (153Sm has a half-life of ~47 h, Eβ(max) = 0.81 MeV, and Eγ = 103 keV (28%)) (2). In addition, both of these bone pain palliative agents are known to produce myelotoxicity in some patients (4). Between the two labeled compounds, 89SrCl2 appears to be the agent of choice for clinical applications because of its longer half-life, which provides the flexibility to develop a suitable treatment regimen for the patient. There is much interest to develop alternative radiolabeled compounds that do not suppress the bone marrow but are suitable to treat pain resulting from osseous metastases as discussed by Jansen et al. (4).
Recently, Das et al. evaluated the use of thulium-170 (170Tm has a half-life of ~128 days, Eβ(max) = 968 keV, and Eγ = 84 keV (3.26%)) as an alternative to 89SrCl2 for the development of a bone pain palliative (2). According to these investigators, 170Tm would probably exhibit low myelosupression because it emits β- particles of lower energy than those emitted by 89Sr, and the γ-photons generated by the nuclide can be used for scintigraphy to detect the accumulation and location of the radiolabel in the organs of an animal. This chapter describes the biodistribution of 170Tm-labeled EDTMP (170Tm-EDTMP) in normal Wistar rats (2).

Chemicals Related in the Paper:

Catalog Number	Product Name	Structure	CAS Number	Price
AP13812812	Strontium pyrophosphate		13812-81-2	Price

As a specialist in analytical chemical Products, Alfa Chemistry offers consumers a wealth of raw materials and a full range of technologies and services.

QUICK LINKS

HEADQUARTERS

Tel:

Fax:

Email: